669 reports of this reaction
1.7% of all Brilinta reports
#11 most reported adverse reaction
HAEMORRHAGE is the #11 most commonly reported adverse reaction for Brilinta, manufactured by Rising Pharma Holdings, Inc.. There are 669 FDA adverse event reports linking Brilinta to HAEMORRHAGE. This represents approximately 1.7% of all 39,143 adverse event reports for this drug.
Patients taking Brilinta who experience haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMORRHAGE is a less commonly reported adverse event for Brilinta, but still significant enough to appear in the safety profile.
In addition to haemorrhage, the following adverse reactions have been reported for Brilinta:
The following drugs have also been linked to haemorrhage in FDA adverse event reports:
HAEMORRHAGE has been reported as an adverse event in 669 FDA reports for Brilinta. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMORRHAGE accounts for approximately 1.7% of all adverse event reports for Brilinta, making it a notable side effect.
If you experience haemorrhage while taking Brilinta, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.